XORTX Historical Financial Ratios

XRTX Stock

USD 1.05 0.02 1.94%

XORTX Therapeutics is currently reporting on over 87 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0, PTB Ratio of 0.88 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate XORTX Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

About XORTX Financial Ratios Analysis

XORTX TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate XORTX Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on XORTX financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across XORTX Therapeutics history.

XORTX Therapeutics Financial Ratios Chart

At this time, XORTX Therapeutics' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 0.88 in 2025, whereas Book Value Per Share is likely to drop 1.59 in 2025.

Price To Sales Ratio Days Sales Outstanding Book Value Per Share Average Payables Stock Based Compensation To Revenue

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing XORTX Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on XORTX Therapeutics sales, a figure that is much harder to manipulate than other XORTX Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Stock Based Compensation To Revenue

A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.

Most ratios from XORTX Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.At this time, XORTX Therapeutics' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 0.88 in 2025, whereas Book Value Per Share is likely to drop 1.59 in 2025.

XORTX Therapeutics fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow
Ptb Ratio		0.44	-0.4	-0.56	-0.07	0.41	1.0	-0.59	-0.88	-0.24	-0.37	0.25	0.14	-0.02	0.35	0.34	-0.35	0.02	0.3	-0.5	0.37	-0.61	0.47	-0.21	0.21	0.42
Book Value Per Share	0.44		-0.02	-0.71	0.52	0.3	0.44	-0.72	-0.37	-0.17	0.06	0.19	0.05	-0.07	0.89	-0.59	-0.59	0.12	-0.62	-0.05	0.63	-0.06	-0.16	-0.89	0.42	-0.23
Free Cash Flow Yield	-0.4	-0.02		0.21	0.3	-0.24	-0.4	0.27	0.57	0.18	-0.07	-0.17	-0.3	-0.32	0.34	-0.27	0.01	0.56	-0.25	0.42	-0.55	0.44	0.06	-0.23	-0.19	0.11
Operating Cash Flow Per Share	-0.56	-0.71	0.21		-0.53	0.08	-0.56	1.0	0.58	0.73	0.36	-0.75	-0.46	-0.1	-0.69	0.22	0.87	-0.34	0.27	0.43	-0.46	0.27	-0.06	0.4	-0.36	0.03
Average Payables	-0.07	0.52	0.3	-0.53		-0.47	-0.07	-0.48	-0.07	-0.44	-0.15	0.47	0.3	0.09	0.54	-0.55	-0.61	0.62	-0.59	-0.04	0.04	0.1	-0.24	-0.34	0.33	-0.3
Capex To Depreciation	0.41	0.3	-0.24	0.08	-0.47		0.41	0.03	-0.2	0.62	-0.09	-0.62	-0.57	-0.39	0.23	-0.16	0.36	-0.51	-0.14	0.3	0.16	-0.4	-0.16	-0.43	-0.23	-0.14
Pb Ratio	1.0	0.44	-0.4	-0.56	-0.07	0.41		-0.59	-0.88	-0.24	-0.37	0.25	0.14	-0.02	0.35	0.34	-0.35	0.02	0.3	-0.5	0.37	-0.61	0.47	-0.21	0.21	0.42
Free Cash Flow Per Share	-0.59	-0.72	0.27	1.0	-0.48	0.03	-0.59		0.6	0.71	0.32	-0.72	-0.44	-0.09	-0.68	0.19	0.85	-0.26	0.25	0.43	-0.52	0.27	-0.06	0.4	-0.38	0.02
Roic	-0.88	-0.37	0.57	0.58	-0.07	-0.2	-0.88	0.6		0.34	0.4	-0.34	-0.3	-0.16	-0.18	-0.35	0.36	-0.13	-0.29	0.53	-0.4	0.76	-0.44	0.07	-0.49	-0.36
Inventory Turnover	-0.24	-0.17	0.18	0.73	-0.44	0.62	-0.24	0.71	0.34		0.19	-0.99	-0.85	-0.53	-0.21	-0.16	0.87	-0.45	-0.11	0.74	-0.29	0.0	-0.24	-0.11	-0.23	-0.18
Net Income Per Share	-0.37	0.06	-0.07	0.36	-0.15	-0.09	-0.37	0.32	0.4	0.19		-0.21	0.05	0.27	-0.15	-0.12	0.14	-0.48	-0.09	0.0	0.53	0.73	-0.16	-0.2	0.16	-0.14
Days Of Inventory On Hand	0.25	0.19	-0.17	-0.75	0.47	-0.62	0.25	-0.72	-0.34	-0.99	-0.21		0.83	0.48	0.23	0.15	-0.87	0.45	0.1	-0.72	0.28	0.0	0.24	0.11	0.23	0.17
Payables Turnover	0.14	0.05	-0.3	-0.46	0.3	-0.57	0.14	-0.44	-0.3	-0.85	0.05	0.83		0.88	0.01	0.22	-0.74	0.36	0.18	-0.88	0.38	0.01	0.24	0.11	0.19	0.19
Average Inventory	-0.02	-0.07	-0.32	-0.1	0.09	-0.39	-0.02	-0.09	-0.16	-0.53	0.27	0.48	0.88		-0.18	0.19	-0.45	0.21	0.16	-0.76	0.37	0.03	0.15	0.07	0.11	0.12
Cash Per Share	0.35	0.89	0.34	-0.69	0.54	0.23	0.35	-0.68	-0.18	-0.21	-0.15	0.23	0.01	-0.18		-0.58	-0.64	0.37	-0.6	0.02	0.33	0.01	-0.07	-0.87	0.2	-0.11
Pocfratio	0.34	-0.59	-0.27	0.22	-0.55	-0.16	0.34	0.19	-0.35	-0.16	-0.12	0.15	0.22	0.19	-0.58		0.17	-0.02	1.0	-0.48	-0.09	-0.25	0.81	0.65	0.06	0.82
Interest Coverage	-0.35	-0.59	0.01	0.87	-0.61	0.36	-0.35	0.85	0.36	0.87	0.14	-0.87	-0.74	-0.45	-0.64	0.17		-0.52	0.22	0.63	-0.44	-0.01	-0.14	0.38	-0.28	-0.07
Capex To Operating Cash Flow	0.02	0.12	0.56	-0.34	0.62	-0.51	0.02	-0.26	-0.13	-0.45	-0.48	0.45	0.36	0.21	0.37	-0.02	-0.52		-0.06	-0.19	-0.32	-0.15	0.37	-0.11	0.25	0.34
Pfcf Ratio	0.3	-0.62	-0.25	0.27	-0.59	-0.14	0.3	0.25	-0.29	-0.11	-0.09	0.1	0.18	0.16	-0.6	1.0	0.22	-0.06		-0.44	-0.11	-0.21	0.79	0.66	0.01	0.81
Days Payables Outstanding	-0.5	-0.05	0.42	0.43	-0.04	0.3	-0.5	0.43	0.53	0.74	0.0	-0.72	-0.88	-0.76	0.02	-0.48	0.63	-0.19	-0.44		-0.41	0.15	-0.45	-0.14	-0.09	-0.41
Income Quality	0.37	0.63	-0.55	-0.46	0.04	0.16	0.37	-0.52	-0.4	-0.29	0.53	0.28	0.38	0.37	0.33	-0.09	-0.44	-0.32	-0.11	-0.41		0.08	0.05	-0.49	0.53	-0.01
Roe	-0.61	-0.06	0.44	0.27	0.1	-0.4	-0.61	0.27	0.76	0.0	0.73	0.0	0.01	0.03	0.01	-0.25	-0.01	-0.15	-0.21	0.15	0.08		-0.23	-0.1	-0.15	-0.18
Ev To Operating Cash Flow	0.47	-0.16	0.06	-0.06	-0.24	-0.16	0.47	-0.06	-0.44	-0.24	-0.16	0.24	0.24	0.15	-0.07	0.81	-0.14	0.37	0.79	-0.45	0.05	-0.23		0.18	0.36	0.99
Pe Ratio	-0.21	-0.89	-0.23	0.4	-0.34	-0.43	-0.21	0.4	0.07	-0.11	-0.2	0.11	0.11	0.07	-0.87	0.65	0.38	-0.11	0.66	-0.14	-0.49	-0.1	0.18		-0.23	0.21
Return On Tangible Assets	0.21	0.42	-0.19	-0.36	0.33	-0.23	0.21	-0.38	-0.49	-0.23	0.16	0.23	0.19	0.11	0.2	0.06	-0.28	0.25	0.01	-0.09	0.53	-0.15	0.36	-0.23		0.28
Ev To Free Cash Flow	0.42	-0.23	0.11	0.03	-0.3	-0.14	0.42	0.02	-0.36	-0.18	-0.14	0.17	0.19	0.12	-0.11	0.82	-0.07	0.34	0.81	-0.41	-0.01	-0.18	0.99	0.21	0.28

Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	1.0	1.87	2.14	0.93	0.84	0.88
Book Value Per Share	(0.36)	1.7	12.04	4.71	2.34	2.11
Free Cash Flow Yield	(0.23)	(0.59)	(0.2)	(1.53)	(1.38)	(1.31)
Operating Cash Flow Per Share	(0.98)	(4.36)	(5.96)	(3.32)	(3.82)	(4.01)
Capex To Depreciation	0.7	2.23	0.8	0.45	0.52	0.49
Pb Ratio	1.0	1.87	2.14	0.93	0.84	0.88
Free Cash Flow Per Share	(1.0)	(4.39)	(5.99)	(3.35)	(3.85)	(4.04)
Roic	(1.05)	(0.32)	(0.98)	(0.93)	(1.07)	(1.01)
Net Income Per Share	(1.73)	(1.19)	(4.72)	(1.44)	(1.66)	(1.74)
Payables Turnover	0.0668	0.0552	0.0582	0.72	0.65	0.69
Cash Per Share	0.23	13.56	7.03	1.74	1.57	2.09
Pocfratio	(1.73)	(5.16)	(1.69)	(0.66)	(0.76)	(0.79)
Interest Coverage	(51.9)	(15.21)	(96.25)	(941.98)	(1.1K)	(1.0K)
Capex To Operating Cash Flow	(0.0197)	(0.006566)	(0.005015)	(0.007157)	(0.006441)	(0.006763)
Pfcf Ratio	(4.36)	(1.69)	(5.12)	(1.68)	(0.75)	(0.79)
Days Payables Outstanding	5.5K	6.6K	6.3K	503.47	578.99	550.04
Income Quality	0.57	3.67	1.26	3.05	2.75	2.88
Roe	(1.02)	(0.0987)	(1.0)	(0.62)	(0.55)	(0.58)
Ev To Operating Cash Flow	(4.45)	(1.49)	(2.05)	(0.52)	(0.14)	(0.16)
Pe Ratio	(0.98)	(18.93)	(2.13)	(1.52)	(1.74)	(1.83)
Return On Tangible Assets	(0.62)	(0.0759)	(0.58)	(0.54)	(0.49)	(0.51)
Ev To Free Cash Flow	(4.33)	(1.46)	(2.04)	(0.52)	(0.14)	(0.16)
Earnings Yield	(1.02)	(0.0528)	(0.47)	(0.66)	(0.59)	(0.62)
Intangibles To Total Assets	0.1	0.0116	0.0162	0.0321	0.0369	0.035
Net Debt To E B I T D A	0.14	9.08	1.1	0.53	0.48	0.92
Current Ratio	1.99	3.81	7.19	13.8	12.42	13.04
Tangible Book Value Per Share	1.38	11.86	4.58	2.25	2.03	1.22
Shareholders Equity Per Share	(0.36)	1.7	12.04	4.71	2.34	2.11
Debt To Equity	0.13	(0.24)	0.0111	0.00248	0.002232	0.002343
Capex Per Share	0.0194	0.0286	0.0299	0.0238	0.0273	0.026
Interest Debt Per Share	0.0182	0.004028	0.0523	0.005808	0.006679	0.006345
Debt To Assets	0.0342	0.0467	0.006274	0.002105	0.002421	0.0023
Enterprise Value Over E B I T D A	(0.87)	(5.98)	(0.49)	(0.14)	(0.16)	(0.17)
Price Earnings Ratio	(0.98)	(18.93)	(2.13)	(1.52)	(1.74)	(1.83)
Price Book Value Ratio	1.0	1.87	2.14	0.93	0.84	0.88
Price Earnings To Growth Ratio	(0.0155)	0.61	(0.007196)	0.0218	0.0196	0.0186

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

XORTX Historical Financial Ratios

About XORTX Financial Ratios Analysis

XORTX Therapeutics Financial Ratios Chart

Price To Sales Ratio

Book Value Per Share

Average Payables

Stock Based Compensation To Revenue

XORTX Therapeutics fundamentals Correlations

XORTX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

XORTX Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for XORTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 0.99	Ev To Operating Cash Flow
Cash Per Share	+ 0.89	Book Value Per Share
Average Inventory	+ 0.88	Payables Turnover

Days Of Inventory On Hand	- 0.99	Inventory Turnover
Pe Ratio	- 0.89	Book Value Per Share
Days Payables Outstanding	- 0.88	Payables Turnover
Roic	- 0.88	Pb Ratio
Roic	- 0.88	Ptb Ratio
Pe Ratio	- 0.87	Cash Per Share